NGF: Beta-nerve growth factor
Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems.
- Drugs that act on it: 5
- Approved: 0
- In phases 1 to 3: 5
- Sponsors: 5
Who is on it, and how far along
Every drug ChEMBL records acting on NGF, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 3
- Other 2
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Abbott Laboratories120%
- Amgen120%
- AstraZeneca Pharmaceuticals120%
- Pfizer120%
- Regeneron120%
| Fasinumab | Phase 3 | Regeneron | Antibody | Inhibitor | 0 |
| Fulranumab | Phase 3 | Amgen | Antibody | Inhibitor | 0 |
| Tanezumab | Phase 3 | Pfizer | Antibody | Inhibitor | 0 |
| MEDI-578 | Phase 1 | AstraZeneca Pharmaceuticals | Other | Inhibitor | 0 |
| PG-110 | Phase 1 | Abbott Laboratories | Other | Inhibitor | 0 |
- Hereditary sensory and autonomic neuropathy type 50.77
- Osteoarthritis, knee0.56
- Hypertensive disorder0.54
- Pain0.52
- Osteoarthritis0.51
- Spinal stenosis0.51
- Osteoarthritis, hip0.49
- Essential hypertension0.49
- Coronary artery disorder0.47
- Angina pectoris0.45
- Endometriosis0.43
- Total joint arthroplasty0.41
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1649058, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P01138, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets